Welcome to our dedicated page for Cybin SEC filings (Ticker: CYBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CYBN SEC filings page on Stock Titan aggregates Cybin Inc.’s regulatory disclosures as a foreign issuer, giving investors structured access to the company’s official documents. Cybin files with the U.S. Securities and Exchange Commission primarily on Form 40-F and Form 6-K, and also uses Form 25 for listing changes. These filings are central to understanding the company’s clinical-stage neuropsychiatry business, its capital structure, and its transition between stock exchanges.
Form 6-K submissions for Cybin typically include interim consolidated financial statements, management’s discussion and analysis, certifications of interim filings, and news releases. Many 6-Ks also incorporate material change reports, equity distribution agreements, and prospectus-related documents by reference into Cybin’s registration statements on Form F-10. For a company developing drug candidates such as CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder, these filings provide context on how clinical programs are funded and governed.
The filings page also features Cybin’s Form 25, which notifies the SEC of the voluntary removal of its common shares from listing and registration on the NYSE American. This document confirms that the company has complied with the exchange’s rules and the requirements for voluntary withdrawal, and it aligns with Cybin’s news release describing its plan to transfer its U.S. listing to the Nasdaq Global Market and to change its trading symbol from CYBN to HELP.
On Stock Titan, each new Cybin filing from EDGAR is captured and presented with AI-powered summaries that explain the purpose and key points of documents such as 6-Ks, F-10 registration statements, and the Form 25 delisting notice. This helps readers quickly understand how Cybin reports its financial results, documents material changes, and manages its listing status, while still allowing direct access to the underlying SEC filings for detailed review.
Cybin Inc., operating as Helus Pharma, furnished a Form 6-K highlighting a new collaboration between Helus Pharma and TARA Mind to support recruitment for the HLP003 Phase 3 program in Major Depressive Disorder, which has FDA Breakthrough Therapy Designation.
The partnership focuses on outreach to veteran communities, aligning with a recent U.S. Executive Order that promotes access to innovative mental health treatments for high‑risk groups such as veterans. TARA Mind will use its veteran-focused networks and collaborative care platform to expand awareness of clinical research opportunities and mental health resources.
The filing also reiterates that Helus Pharma is a clinical-stage company developing proprietary novel serotonergic agonists (NSAs), including HLP003 for adjunctive treatment of major depressive disorder and HLP004 in Phase 2 for generalized anxiety disorder, supported by a broader research portfolio across several countries.
Cybin Inc., operating commercially as Helus Pharma, filed a Form 6-K to share a news release about an upcoming conference appearance and to describe its clinical pipeline. Interim CEO Eric So will speak on a Milken Institute Global Conference panel titled “The Next Wave of Health Innovation” on May 4, 2026, with a live and archived webcast available on the company’s investor relations site.
Helus Pharma is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs) aimed at improving treatments for depression, anxiety and other mental health conditions. Lead candidate HLP003 is in Phase 3 development for adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, while HLP004 is in Phase 2 for generalized anxiety disorder. The release includes extensive cautionary language, emphasizing that NSAs and the company’s product candidates have not been approved by regulators, their efficacy has not been confirmed, and further clinical research and regulatory approvals are required.
Cybin Inc., operating as Helus Pharma, filed a Form 6-K highlighting a new collaboration with TARA Mind, which works with Veterans Exploring Treatment Solutions, to support recruitment for the HLP003 Phase 3 program in Major Depressive Disorder and expand mental health outreach in veteran communities.
HLP003 is a proprietary novel serotonergic agonist in Phase 3 clinical development as an adjunctive treatment for major depressive disorder and has Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Helus Pharma is also developing HLP004, another NSA in Phase 2 for generalized anxiety disorder, alongside a broader research portfolio targeting unmet mental health needs.
Cybin Inc., operating commercially as Helus Pharma, filed a Form 6-K furnishing a press release announcing that Helus Pharma has added Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board. The board is chaired by Dr. Freda Lewis-Hall and supports the company’s clinical and regulatory strategy.
The release highlights Helus Pharma’s pipeline of proprietary novel serotonergic agonists, including HLP003 in Phase 3 development for adjunctive treatment of major depressive disorder with U.S. FDA Breakthrough Therapy Designation, and HLP004 in Phase 2 for generalized anxiety disorder, along with an extensive research portfolio of investigational NSAs.
Cybin Inc. Schedule 13G/A amends joint beneficial ownership disclosures for several Millennium-related filers and Israel A. Englander. The filing reports Integrated Core Strategies (US) LLC beneficially holds 2,730,560 shares (5.5%) and that Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each report 2,829,893 shares (5.7%).
The filing states these holdings reflect shared voting and dispositive power and attaches a Joint Filing Agreement dated April 21, 2026. Signatures are provided by Gil Raviv and Israel A. Englander.
Cybin Inc., operating as Helus Pharma, filed a Form 6-K featuring a news update on a White House Executive Order intended to accelerate research, regulation, and patient access for psychedelic-based treatments for serious mental health conditions.
The company states that this policy focus aligns with its portfolio of novel serotonergic agonists. Its lead drug candidate, HLP003, is in Phase 3 clinical development as an adjunctive treatment for major depressive disorder and has received U.S. FDA Breakthrough Therapy designation. A second candidate, HLP004, is in Phase 2 development for generalized anxiety disorder.
The update emphasizes that Helus Pharma continues to advance late-stage trials and broader NSA research while engaging regulators, clinicians, and partners. It also reiterates that none of its investigational products are approved and that extensive clinical and regulatory work remains before any potential commercialization.
Cybin Inc., operating as Helus Pharma, reports a leadership change, with Michael Cola stepping down as Chief Executive Officer effective immediately at the request of the Board. Co-founder and Executive Chairman Eric So has been appointed Interim Chief Executive Officer while a search for a permanent CEO is conducted.
The company reiterates its focus on advancing its clinical pipeline of novel serotonergic agonists, including HLP003 in Phase 3 for adjunctive treatment of major depressive disorder and HLP004 in Phase 2 for generalized anxiety disorder. Helus highlights an upcoming topline data readout from the Phase 3 APPROACH trial of HLP003 expected in the fourth quarter.
Cybin Inc., operating commercially as Helus Pharma, used this report to share that Helus has appointed Dr. Ken Kramer as Senior Vice President, Medical Affairs. He brings more than 25 years of neuroscience medical affairs experience from roles at Bristol Myers Squibb, Karuna Therapeutics, and AbbVie.
The company highlights its focus on developing proprietary novel serotonergic agonists (NSAs) for mental health conditions. Its lead NSA, HLP003, is in Phase 3 clinical development for adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation, while HLP004 is in Phase 2 for generalized anxiety disorder.
Cybin Inc. Schedule 13G discloses that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared beneficial ownership of 2,514,667 common shares, representing 5.0% of the class as of 04/07/2026. The filing is a joint filing under a signed agreement dated 04/09/2026.
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reported beneficial ownership of 2,397,721 Common Shares (4.8%) of Cybin Inc.
The filing states these reporting persons acquired beneficial ownership in excess of 5% on 03/19/2026 but ceased to be beneficial owners of more than 5% by the date of this Schedule 13G filing. The submission includes a Joint Filing Agreement dated 03/25/2026.